Skip to main content
SpringerLink
Log in

Planning and Assessment of Bioequivalence Studies of Darunavir Preparations

  • DRUGS
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

Planning issues for darunavir (DRV) bioequivalence studies are considered. DRV is an antiviral (HIV) agent classified as an HIV protease inhibitor. Bioequivalence test results must be submitted for registration of generic drugs in the RF according to Federal Law 61-FZ. Bioequivalence study protocols and reports for DRV preparations that were submitted for review to the SCEEMP were analyzed. Differences in study designs including administration after fasting or meals, with or without a low dose of ritonavir, numbers of volunteers included in the study, and intra-subject variability were found. The internet was also searched for data on DRV variability. Recommendations for planning bioequivalence studies of DRV preparations were formulated based on the analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. J. Robertson and J. Feinberg, Expert Opin. Pharmacother., 13(9), 1363 – 1375 (2012).

    Article  CAS  Google Scholar 

  2. F. Barré-Sinoussi, A. L. Ross, and J. F. Delfraissy, Nat. Rev. Microbiol., 11(12), 877 – 883 (2013).

    Article  Google Scholar 

  3. E. D. Deeks, Drugs, 74(1), 99 – 125 (2014).

    Article  CAS  Google Scholar 

  4. Instructions for Medical Use of Prezista ® , State Drug Registry (2018).

  5. http://itpcru.org/2018/04/18/analiz-zakupok-arv-preparatov-v-rf-v-2017-godu/ (2018)

  6. Russian Federation Federal Law No. 61-FZ dated Apr. 12, 2010 “On circulation of medicines” [in Russian], Moscow (2010).

  7. A. N. Mironov (ed.), Handbook for Drug Review [in Russian], Vol. 1, Grif i K, Moscow (2013), pp. 174 – 215.

  8. Rules for Conducting Bioequivalence Studies of Drugs in the Eurasian Economic Union, approved by Decision No. 85 of the Eurasian Economic Commission Committee dated Nov. 3, 2016, Moscow (2016).

  9. Investigation of Bioequivalence (CPMP / EWP / QWP / 1401 / 98 Rev. 1), European Medicines Agency, London (2013).

  10. http://grls.rosminzdrav.ru/CIPermitionReg.aspx

  11. Assessment Report for Prezista (EMEA / CHMP / 259742 / 2009), European Medicines Agency, London (2009).

  12. A. A. Mathias, S. West, J. Hui, and B. P. Kearney, Clin. Pharmacol. Ther., 85(1), 64 – 70 (2009).

    Article  CAS  Google Scholar 

  13. S. Katzenmaier, C. Markert, K. D. Riedel, et al., Clin. Pharmacol. Ther., 90(5), 666 – 673 (2011).

    Article  CAS  Google Scholar 

  14. C. Eichbaum, M. Cortese, A. Blank, et al., Eur. J. Clin. Pharmacol., 69(10), 1795 – 1800 (2013).

    Article  CAS  Google Scholar 

  15. D. J. Greenblatt, J. Clin. Pharmacol., 56(2), 152 – 156 (2016).

    Article  CAS  Google Scholar 

  16. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204389.pdf

  17. I. B. Bondareva, V. B. Gerasimov, A. P. Drozhzhin, et al., Klin. Farmakokinet., No. 1, 2 – 14 (2005).

  18. Guidance for Industry. Bioavailability and Bioequivalence Studies Submitted in NDAs and INDs: General Considerations, US Dept. Health Human Services, Food and Drug Administration, Rockville, MD (2014).

  19. D. P. Romodanovskii, T. V. Eremenkova, M. A. Dranitsyna, et al., Vedom. Nauchn. Tsentra Ekspert. Sredstv Med. Primeneniya, No. 4, 5 – 10 (2015).

  20. B. M. Davit, D. P. Conner, B. Fabian-Fritsch, et al., AAPS J., 10(1), 148 – 156 (2008).

    Article  CAS  Google Scholar 

  21. S. H. Haidar, B. Davit, M. L. Chen, et al., Pharm. Res., 25(1), 237 – 241 (2008).

    Article  CAS  Google Scholar 

  22. T. N. Kakuda, L. Leopold, M. Timmers, et al., Int. J. Clin. Pharmacol. Ther., 52(9), 805 – 816 (2014).

    Article  CAS  Google Scholar 

  23. https://db.cbg-meb.nl/Pars/h118333.pdf

  24. http://www.ema.europa.eu/docs/enGB/document library/EPAR-Publicassessmentreport/human/004068/WC500220726.pdf (2016).

  25. https://extranet.who.int/prequal/sites/default/files/HA627part6v02.pdf

  26. A. Gupta, P. Singhal, P. S. Shrivastav, and M. Sanyal, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 879(24), 2443 – 2453 (2011).

    CAS  Google Scholar 

  27. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con814242.pdf

  28. T. N. Kakuda, T. Van De Casteele, R. Petrovic, et al., Antiviral Ther., 19(6), 597 – 606 (2014).

  29. http://programme.ias2017.org/Abstract/Abstract/4016 (2017).

  30. https://extranet.who.int/prequal/sites/default/files/documents/14%20BE%20darunavirOct20150.pdf

Download references

Author information

Authors and Affiliations

  1. Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP), Ministry of Health of the Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051, Russia

    N. E. Uvarova, N. N. Eremenko, G. V. Ramenskaya & D. V. Goryachev

Authors
  1. N. E. Uvarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. N. Eremenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. V. Ramenskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. V. Goryachev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. E. Uvarova.

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 52, No. 9, pp. 22 – 26, September, 2018.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uvarova, N.E., Eremenko, N.N., Ramenskaya, G.V. et al. Planning and Assessment of Bioequivalence Studies of Darunavir Preparations. Pharm Chem J 52, 771–775 (2018). https://doi.org/10.1007/s11094-018-1897-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-018-1897-z

Keywords

Search

Navigation